Four‐week outcomes of vascular endothelial growth factor inhibitors for neovascular age‐related macular degeneration

MLA

Mark C Gillies, et al. “Four‐week Outcomes of Vascular Endothelial Growth Factor Inhibitors for Neovascular Age‐related Macular Degeneration.” Clinical & Experimental Ophthalmology, vol. 48, June 2020, pp. 946–55. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e31630581a33099b9a0a5120bf9c8083&authtype=sso&custid=ns315887.

APA

Mark C Gillies, Peter Hinchcliffe, Daniel Barthelmes, Ross Ferrier, Vuong Nguyen, Shaan Wiryasaputra, & Jennifer J. Arnold. (2020). Four‐week outcomes of vascular endothelial growth factor inhibitors for neovascular age‐related macular degeneration. Clinical & Experimental Ophthalmology, 48, 946–955.

Chicago

Mark C Gillies, Peter Hinchcliffe, Daniel Barthelmes, Ross Ferrier, Vuong Nguyen, Shaan Wiryasaputra, and Jennifer J. Arnold. 2020. “Four‐week Outcomes of Vascular Endothelial Growth Factor Inhibitors for Neovascular Age‐related Macular Degeneration.” Clinical & Experimental Ophthalmology 48 (June): 946–55. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e31630581a33099b9a0a5120bf9c8083&authtype=sso&custid=ns315887.